Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.41 |
| ▸ | RPTOR | Q8N122 | 5/20 | 0.41 |
| ▸ | MLST8 | Q9BVC4 | 5/20 | 0.41 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.30 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22693230 | 0.90 | MTOR (0.43) | MTORRPTORMLST8SMN1; SMN2 | |
| SCHEMBL22693231 | 0.90 | MTOR (0.43) | MTORRPTORMLST8FASNSMN1; SMN2 | |
| SCHEMBL22693175 | 0.88 | MTOR (0.48) | MTORRPTORMLST8FASNSMN1; SMN2 | |
| SCHEMBL22693115 | 0.88 | MTOR (0.52) | MTORRPTORMLST8FASNSMN1; SMN2 | |
| SCHEMBL22693149 | 0.88 | MTOR (0.52) | MTORRPTORMLST8FASNSMN1; SMN2 | |
| SCHEMBL22693268 | 0.86 | MTOR (0.49) | MTORRPTORMLST8DCTPP1SMN1; SMN2 | |
| SCHEMBL22693120 | 0.82 | MTOR (0.51) | MTORRPTORMLST8FASNSMN1; SMN2 | |
| SCHEMBL21360299 | 0.81 | MTOR (0.61) | MTORRPTORMLST8FASN | |
| SCHEMBL22693166 | 0.81 | MTOR (0.61) | MTORRPTORMLST8FASN | |
| SCHEMBL21360291 | 0.81 | MTOR (0.61) | MTORRPTORMLST8FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.